Atefe Abak

2.0k total citations
51 papers, 1.4k citations indexed

About

Atefe Abak is a scholar working on Cancer Research, Molecular Biology and Oncology. According to data from OpenAlex, Atefe Abak has authored 51 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Cancer Research, 41 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Atefe Abak's work include Cancer-related molecular mechanisms research (33 papers), MicroRNA in disease regulation (26 papers) and Circular RNAs in diseases (19 papers). Atefe Abak is often cited by papers focused on Cancer-related molecular mechanisms research (33 papers), MicroRNA in disease regulation (26 papers) and Circular RNAs in diseases (19 papers). Atefe Abak collaborates with scholars based in Iran, Iraq and Germany. Atefe Abak's co-authors include Mohammad Taheri, Soudeh Ghafouri‐Fard, Hamed Shoorei, Bashdar Mahmud Hussen, Alireza Abhari, Jamal Majidpoor, Farhad Tondro Anamag, Abbas Basiri, Mahdi Mohaqiq and Nader Akbari Dilmaghani and has published in prestigious journals such as Frontiers in Immunology, European Journal of Pharmacology and Biomedicine & Pharmacotherapy.

In The Last Decade

Atefe Abak

50 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Atefe Abak Iran 24 965 830 133 124 95 51 1.4k
Gang Luo China 17 1.0k 1.1× 755 0.9× 107 0.8× 85 0.7× 129 1.4× 54 1.4k
Jing Ni China 19 654 0.7× 422 0.5× 165 1.2× 134 1.1× 91 1.0× 66 1.2k
Binghui Li China 19 596 0.6× 445 0.5× 131 1.0× 96 0.8× 99 1.0× 44 1.0k

Countries citing papers authored by Atefe Abak

Since Specialization
Citations

This map shows the geographic impact of Atefe Abak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atefe Abak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atefe Abak more than expected).

Fields of papers citing papers by Atefe Abak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atefe Abak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atefe Abak. The network helps show where Atefe Abak may publish in the future.

Co-authorship network of co-authors of Atefe Abak

This figure shows the co-authorship network connecting the top 25 collaborators of Atefe Abak. A scholar is included among the top collaborators of Atefe Abak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atefe Abak. Atefe Abak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taheri, Mohammad, et al.. (2025). Significant upregulation of prenyltransferase-related genes in neuromyelitis optica: Diagnostic potential and clinical correlations. Multiple Sclerosis and Related Disorders. 102. 106622–106622.
2.
Ghafouri‐Fard, Soudeh, Bashdar Mahmud Hussen, Hamed Shoorei, et al.. (2023). Interactions between non-coding RNAs and HIF-1α in the context of cancer. European Journal of Pharmacology. 943. 175535–175535. 9 indexed citations
3.
Gholipour, Mahdi, Bashdar Mahmud Hussen, Atefe Abak, et al.. (2022). Expression of NF-κB-associated lncRNAs in different types of migraine. Acta Neurologica Belgica. 123(5). 1823–1831. 4 indexed citations
4.
Taheri, Mohammad, Bashdar Mahmud Hussen, Sajad Najafi, et al.. (2022). Molecular mechanisms of inhibitor of growth (ING) family members in health and malignancy. Cancer Cell International. 22(1). 272–272. 7 indexed citations
5.
Ghafouri‐Fard, Soudeh, et al.. (2022). NLRP3: Role in ischemia/reperfusion injuries. Frontiers in Immunology. 13. 926895–926895. 22 indexed citations
6.
Ghafouri‐Fard, Soudeh, et al.. (2022). Aberrant expression of miRNAs in epilepsy. Molecular Biology Reports. 49(6). 5057–5074. 28 indexed citations
7.
Karimipour, Mojtaba, et al.. (2022). Protective effects of chlorogenic acid against ionizing radiation-induced testicular toxicity. Heliyon. 8(10). e10798–e10798. 8 indexed citations
8.
Ghafouri‐Fard, Soudeh, Atefe Abak, Bashdar Mahmud Hussen, Mohammad Taheri, & Guive Sharifi. (2021). The Emerging Role of Non-Coding RNAs in Pituitary Gland Tumors and Meningioma. Cancers. 13(23). 5987–5987. 24 indexed citations
9.
Ghafouri‐Fard, Soudeh, Hamed Shoorei, Zahra Bahroudi, Atefe Abak, & Mohammad Taheri. (2021). The role of H19 lncRNA in conferring chemoresistance in cancer cells. Biomedicine & Pharmacotherapy. 138. 111447–111447. 22 indexed citations
10.
Ghafouri‐Fard, Soudeh, Atefe Abak, Zahra Bahroudi, et al.. (2021). The interplay between non-coding RNAs and Twist1 signaling contribute to human disorders. Biomedicine & Pharmacotherapy. 135. 111220–111220. 10 indexed citations
11.
Ghafouri‐Fard, Soudeh, et al.. (2021). MicroRNAs as important contributors in the pathogenesis of colorectal cancer. Biomedicine & Pharmacotherapy. 140. 111759–111759. 35 indexed citations
12.
Ghafouri‐Fard, Soudeh, Atefe Abak, Farhad Tondro Anamag, et al.. (2021). 5-Fluorouracil: A Narrative Review on the Role of Regulatory Mechanisms in Driving Resistance to This Chemotherapeutic Agent. Frontiers in Oncology. 11. 658636–658636. 116 indexed citations
13.
Hussen, Bashdar Mahmud, et al.. (2021). Role of lncRNA BANCR in Human Cancers: An Updated Review. Frontiers in Cell and Developmental Biology. 9. 689992–689992. 40 indexed citations
14.
Ghafouri‐Fard, Soudeh, Atefe Abak, Mahdi Mohaqiq, Hamed Shoorei, & Mohammad Taheri. (2021). Interaction between non-coding RNAs and JNK in human disorders. Biomedicine & Pharmacotherapy. 138. 111497–111497. 4 indexed citations
15.
Ghafouri‐Fard, Soudeh, Atefe Abak, Seyedeh Fahimeh Talebi, et al.. (2021). Role of miRNA and lncRNAs in organ fibrosis and aging. Biomedicine & Pharmacotherapy. 143. 112132–112132. 107 indexed citations
16.
Ghafouri‐Fard, Soudeh, Atefe Abak, Hamed Shoorei, et al.. (2021). Functional roles of non-coding RNAs in atrophy. Biomedicine & Pharmacotherapy. 141. 111820–111820. 4 indexed citations
17.
Ghafouri‐Fard, Soudeh, et al.. (2021). LncRNA ZFAS1: Role in tumorigenesis and other diseases. Biomedicine & Pharmacotherapy. 142. 111999–111999. 24 indexed citations
18.
Ghafouri‐Fard, Soudeh, et al.. (2021). Emerging roles of miRNAs in the development of pancreatic cancer. Biomedicine & Pharmacotherapy. 141. 111914–111914. 51 indexed citations
19.
Safa, Amin, Zahra Bahroudi, Hamed Shoorei, et al.. (2020). miR-1: A comprehensive review of its role in normal development and diverse disorders. Biomedicine & Pharmacotherapy. 132. 110903–110903. 44 indexed citations
20.
Safa, Amin, Atefe Abak, Hamed Shoorei, Mohammad Taheri, & Soudeh Ghafouri‐Fard. (2020). MicroRNAs as regulators of ERK/MAPK pathway: A comprehensive review. Biomedicine & Pharmacotherapy. 132. 110853–110853. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gang Luo Breakdown of academic impact, for papers by Jing Ni Breakdown of academic impact, for papers by Binghui Li
Rankless by CCL
2026